Jiangsu Hengrui Medicine
Jiangsu Hengrui is the largest pharmaceutical company in China and a leader in cancer treatment drugs and anesthetics for surgery. Its profit rose 14% in the first nine months of 2020, alongside a 15% jump in revenue. The company’s status as a domestic pioneer in novel drug development—its recent drug successes include immunotherapy medications and long-lasting insulin treatments—means it’s been hurt less than some of its peers by the Chinese government’s efforts to drive down generic drug prices. Over the past five years, Jiangsu’s stock is up some 350%.
As of 12/3/20
Market Value ($M)
Figures are for the latest twelve months ended Sept. 30, 2020. Market Value as of Nov. 20, 2020. Sources: Bloomberg; S&P Global.
Future 50As of 12/3/20
|Year||Revenues ($M)||Profits ($M)|
Lists ranking Jiangsu Hengrui Medicine